

Srihari Gopal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/121700/publications.pdf>

Version: 2024-02-01

86
papers

13,381
citations

136740

32
h-index

56606

83
g-index

86
all docs

86
docs citations

86
times ranked

19237
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Biological insights from 108 schizophrenia-associated genetic loci. <i>Nature</i> , 2014, 511, 421-427. | 13.7 | 6,934 |
| 2 | Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. <i>American Journal of Human Genetics</i> , 2015, 97, 576-592. | 2.6 | 1,098 |
| 3 | Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508. | 13.7 | 929 |
| 4 | Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. <i>Cell</i> , 2018, 173, 1705-1715.e16. | 13.5 | 623 |
| 5 | Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11 Common Diseases. <i>American Journal of Human Genetics</i> , 2014, 95, 535-552. | 2.6 | 569 |
| 6 | Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , 2010, 116, 107-117. | 1.1 | 225 |
| 7 | Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. <i>Nature Neuroscience</i> , 2016, 19, 420-431. | 7.1 | 204 |
| 8 | A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 235-244. | 0.7 | 170 |
| 9 | Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 830. | 6.0 | 169 |
| 10 | A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 218-226. | 2.5 | 146 |
| 11 | Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 247-256. | 0.9 | 133 |
| 12 | A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia. <i>Neuropsychopharmacology</i> , 2010, 35, 2072-2082. | 2.8 | 131 |
| 13 | Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw018. | 1.0 | 129 |
| 14 | Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. <i>American Journal of Human Genetics</i> , 2018, 102, 1185-1194. | 2.6 | 119 |
| 15 | Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1022-1031. | 2.5 | 107 |
| 16 | A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. <i>Biological Psychiatry</i> , 2021, 90, 611-620. | 0.7 | 103 |
| 17 | A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. <i>Journal of Psychopharmacology</i> , 2011, 25, 685-697. | 2.0 | 93 |
| 18 | A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 107-118. | 1.0 | 87 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 29-34. | 1.1 | 82 |
| 20 | Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. <i>CNS Drugs</i> , 2021, 35, 39-59. | 2.7 | 67 |
| 21 | Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2010, 26, 377-387. | 0.9 | 66 |
| 22 | Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase I, single-dose, randomized, open-label study. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 330-339. | 1.0 | 63 |
| 23 | Does Half-Life Matter After Antipsychotic Discontinuation?. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e813-e820. | 1.1 | 62 |
| 24 | Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. <i>Biological Psychiatry</i> , 2022, 91, 102-117. | 0.7 | 61 |
| 25 | Dosing and Switching Strategies for Paliperidone Palmitate. <i>CNS Drugs</i> , 2011, 25, 1. | 2.7 | 60 |
| 26 | A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. <i>BMC Psychiatry</i> , 2012, 12, 26. | 1.1 | 52 |
| 27 | Genome-wide association study of paliperidone efficacy. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 7-18. | 0.7 | 42 |
| 28 | Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. <i>International Clinical Psychopharmacology</i> , 2016, 31, 202-209. | 0.9 | 41 |
| 29 | Symptomatic Remission in Patients With Bipolar Mania. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1016-1020. | 1.1 | 41 |
| 30 | Efficacy and Safety of Paliperidone Extended Release in Adolescents With Schizophrenia: A Randomized, Double-Blind Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 126-137.e1. | 0.3 | 39 |
| 31 | Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). <i>Current Medical Research and Opinion</i> , 2011, 27, 1603-1611. | 0.9 | 37 |
| 32 | A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1048-1057. | 1.0 | 36 |
| 33 | Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence. <i>Journal of Clinical Psychiatry</i> , 2018, 79, . | 1.1 | 29 |
| 34 | Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. <i>Annals of General Psychiatry</i> , 2013, 12, 22. | 1.2 | 28 |
| 35 | Risk of Cardiovascular Morbidity With Risperidone or Paliperidone Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 157-161. | 0.7 | 28 |
| 36 | Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. <i>Current Medical Research and Opinion</i> , 2015, 31, 2043-2054. | 0.9 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | <p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p><p>Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1365-1379. | 1.0 | 28 |
| 38 | <p>Patientsâ€™ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire</p><p>Patient Preference and Adherence, 2020, Volume 14, 1093-1102. | 0.8 | 28 |
| 39 | A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. International Journal of Neuropsychopharmacology, 2022, 25, 238-251. | 1.0 | 28 |
| 40 | Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophrenia, 2017, 3, 23. | 2.0 | 27 |
| 41 | Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatric Disease and Treatment, 2011, 7, 93. | 1.0 | 25 |
| 42 | Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention. Current Medical Research and Opinion, 2010, 26, 1471-1484. | 0.9 | 24 |
| 43 | Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia, 2018, 4, 10. | 2.0 | 24 |
| 44 | Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 53, 45-53. | 2.5 | 23 |
| 45 | Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Preference and Adherence, 2016, Volume 10, 2127-2139. | 0.8 | 22 |
| 46 | Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. Neuropsychiatric Disease and Treatment, 2013, 9, 1381. | 1.0 | 21 |
| 47 | Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases. Current Drug Safety, 2011, 6, 43-45. | 0.3 | 20 |
| 48 | Incidence of tardive dyskinesia: a comparison of long&acting injectable and oral paliperidone clinical trial databases. International Journal of Clinical Practice, 2014, 68, 1514-1522. | 0.8 | 18 |
| 49 | Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia. International Clinical Psychopharmacology, 2017, 32, 329-336. | 0.9 | 16 |
| 50 | Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 548-557. | 0.7 | 15 |
| 51 | Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. Patient Preference and Adherence, 2021, Volume 15, 2239-2248. | 0.8 | 15 |
| 52 | Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia. Pharmacogenetics and Genomics, 2015, 25, 173-185. | 0.7 | 14 |
| 53 | <p>Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies</p><p>Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1533-1542. | 1.0 | 14 |
| 54 | An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate. Annals of Pharmacotherapy, 2012, 46, 1322-1330. | 0.9 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2016, 32, 1671-1679. | 0.9 | 12 |
| 56 | Maintenance dose conversion between oral risperidone and paliperidone palmitate 1-month: Practical guidance based on pharmacokinetic simulations. <i>International Journal of Clinical Practice</i> , 2018, 72, e13089. | 0.8 | 12 |
| 57 | Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1364-1370. | 1.1 | 11 |
| 58 | Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2193-2207. | 1.0 | 11 |
| 59 | An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. <i>Perspectives in Psychiatric Care</i> , 2018, 54, 530-538. | 0.9 | 10 |
| 60 | Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 180-182. | 0.7 | 10 |
| 61 | Effect of parental age on treatment response in adolescents with schizophrenia. <i>Schizophrenia Research</i> , 2013, 151, 185-190. | 1.1 | 8 |
| 62 | Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study. <i>CNS Drugs</i> , 2017, 31, 797-808. | 2.7 | 8 |
| 63 | Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia. <i>Psychopharmacology Bulletin</i> , 2011, 44, 54-72. | 0.0 | 8 |
| 64 | Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. <i>Clinical Drug Investigation</i> , 2018, 38, 695-702. | 1.1 | 7 |
| 65 | SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response. <i>Pharmacogenomics</i> , 2014, 15, 1557-1564. | 0.6 | 6 |
| 66 | A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. <i>Innovations in Clinical Neuroscience</i> , 2011, 8, 26-33. | 0.1 | 6 |
| 67 | Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 69. | 1.0 | 5 |
| 68 | Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 744-745. | 0.7 | 5 |
| 69 | Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2016, 31, 315-322. | 0.9 | 5 |
| 70 | Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 499-510. | 0.9 | 5 |
| 71 | Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 567-574. | 0.7 | 5 |
| 72 | Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 224-234. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate. <i>Comprehensive Psychiatry</i> , 2021, 107, 152233. | 1.5 | 5 |
| 74 | Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks™ Treatment in Patients with Clinically Stable Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 3197-3208. | 1.0 | 5 |
| 75 | Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 721. | 1.0 | 4 |
| 76 | Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2807-2816. | 1.0 | 4 |
| 77 | <p>Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 587-602. | 1.0 | 4 |
| 78 | <p>Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 681-690. | 1.0 | 3 |
| 79 | Defining “Adequately Treated” A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 1-9. | 1.0 | 3 |
| 80 | Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532098150. | 1.2 | 3 |
| 81 | Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2019, 180, 223-231. | 1.1 | 2 |
| 82 | Prolongation of Cardiac Ventricular Repolarization Under Paliperidone. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 298-299. | 0.8 | 1 |
| 83 | Methodological challenges in indirect treatment comparisons. <i>International Clinical Psychopharmacology</i> , 2018, 33, 213-216. | 0.9 | 1 |
| 84 | The impracticality of surgically removing intramuscular long-acting injectable antipsychotic medication. <i>American Journal of Emergency Medicine</i> , 2018, 36, 522-523. | 0.7 | 1 |
| 85 | Symptomatic Remission in Patients with Bipolar Mania: Results from a Double-Blind, Placebo-Controlled Trial of Risperidone Monotherapy. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007, 2, 213-224. | 0.0 | 0 |
| 86 | Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?. <i>Psychological Medicine</i> , 2018, 48, 2098-2099. | 2.7 | 0 |